Back to Search Start Over

Patent Issued for Methods, kits, and compositions for enhancing cellular therapy (USPTO 11674120).

Source :
Cancer Vaccine Week; 7/3/2023, p100-100, 1p
Publication Year :
2023

Abstract

Keywords: Antigen-Presenting Cells; Bone Marrow Cells; Brain Cancer; Cancer; Dendritic Cells; Drugs and Therapies; Health and Medicine; Hematology; Hematopoietic; Hematopoietic Stem Cells; Hemic and Immune Systems; Immunization; Immunology; Immunotherapy; Lymph Nodes; Lymphoid Tissue; Mononuclear Phagocyte System; N-substituted Glycines; Oncology; Public Health; Sarcosine; Stem Cell Research; Tetanus Toxoid; Therapy; Tumors; University of Florida Research Foundation Inc.; Vaccination; Vaccines EN Antigen-Presenting Cells Bone Marrow Cells Brain Cancer Cancer Dendritic Cells Drugs and Therapies Health and Medicine Hematology Hematopoietic Hematopoietic Stem Cells Hemic and Immune Systems Immunization Immunology Immunotherapy Lymph Nodes Lymphoid Tissue Mononuclear Phagocyte System N-substituted Glycines Oncology Public Health Sarcosine Stem Cell Research Tetanus Toxoid Therapy Tumors University of Florida Research Foundation Inc. Vaccination Vaccines 100 100 1 07/03/23 20230703 NES 230703 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A patent by the inventors Azari, Hassan (Gainesville, FL, US), Lovaton, Rolando (Lima, PE), Mitchell, Duane (Gainesville, FL, US), Rahman, Maryam (Gainesville, FL, US), filed on March 22, 2017, was published online on June 13, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. A cell culture composition comprising: liquid medium containing sarcosine at a concentration of 6 mM to 1 M, and an antigen presenting cell (APC), wherein the APC is a dendritic cell (DC). In some aspects of the invention the subject may be treated using a strategy for enhancing migration of dendritic cells (DCs) to the local lymph node using other cellular therapies, for example, Provenge (Dendreon), DCVax (Northwest Biotherapeutics), AGS vaccines (Argos Therapeutics), or CAR T cells (Juno Therapeutics, Novartis, Kite Pharma, and Cellestis).". [Extracted from the article]

Details

Language :
English
ISSN :
15436810
Database :
Complementary Index
Journal :
Cancer Vaccine Week
Publication Type :
Periodical
Accession number :
164628936